Advance PDS0101 into a Phase 3 clinical trial for head and neck cancer
Delivered after the deadline (341 days after the deadline)
✓ Person-checked A named analyst checked this outcome against the source passage.
- Announced
- 22 Jan 2024
- Due
- 31 Mar 2024
- Delivered
- 7 Mar 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“plan to advance into a Phase 3 clinical trial in combination with KEYTRUDA® for the treatment of recurrent/metastatic HPV16-positive head and neck cancer in the first quarter 2024”
What we found
Evidence strength B What the grades mean
PDS Biotechnology initiated the Phase 3 VERSATILE-003 trial on March 7, 2025, nearly one year after the Q1 2024 deadline.
-
B PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 February 2025 announcement indicating delayed timeline to Q1 2025
-
D PDS Biotech Announces Updated Results from VERSATILE-002 September 2024 statement that Phase 3 trial was planned to start later that year
-
D PDS Biotech Announces Initiation of VERSATILE-003 Phase 3 Clinical Trial Official company announcement confirming trial initiation on March 7, 2025
Checked 21 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Advance
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you PDS Biotechnology Corp? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-PDSB-000044 · Corrections policy